Appendix A: Key to Acronyms
Updated
Reviewed
General Terms
| Acronym/Abbreviation | Full Name |
|---|---|
| AASLD | American Association for the Study of Liver Diseases |
| ACOG | American College of Obstetricians and Gynecologists |
| ACTG | AIDS Clinical Trials Group |
| anti-HBc | anti-hepatitis B core antibody |
| anti-HBs | hepatitis B surface antibody |
| aOR | adjusted odds ratio |
| APR | Antiretroviral Pregnancy Registry |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AUC | area under the curve |
| AUC0–24h | area under the curve from 0 to 24 hours |
| BMC | bone mineral content |
| BMI | body mass index |
| BHIVA | British HIV Association |
| BSID-III | Bayley Scales of Infant and Toddler Development, Third Edition |
| C12h | concentration at 12 hours postdose |
| C24h | concentration at 24 hours postdose |
| CAR | chimeric antigen receptor |
| cCMV | congenital cytomegalovirus |
| CCR5 | C-C chemokine receptor type 5 |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| CK | creatine kinase |
| CL/F | apparent clearance |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMV | cytomegalovirus |
| COC | combined oral contraceptive |
| COC/P/R | combined oral contraceptive/patch/ring |
| CrCl | creatinine clearance |
| Ctrough | trough concentration |
| CYP | cytochrome P450 |
| DAA | direct-acting antiviral |
| DAIDS | Division of AIDS |
| DBS | dried blood spot |
| DMC | Developmental Milestones Checklist |
| EC | emergency contraception enteric coated |
| EC95 | 95% maximal effective concentration |
| EE | ethinyl estradiol |
| ePPND | enhanced pre- and postnatal development |
| FDA | U.S. Food and Drug Administration |
| FDC | fixed-dose combination |
| GBS | group B streptococcus |
| GMC | geometric mean concentration |
| GMR | geometric mean ratio |
| gp120 | glycoprotein 120 |
| H2 blocker | histamine H2-receptor antagonist |
| HAV | hepatitis A virus |
| HBcAb | hepatitis B core antibody |
| HBIG | hepatitis B immune globulin |
| HBsAb | hepatitis B surface antibody |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HEU | HIV exposed but uninfected |
| HD | high dose |
| HDP | hypertensive disorder of pregnancy |
| HDV | hepatitis D virus |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HUU | HIV unexposed and uninfected |
| IDSA | Infectious Diseases Society of America |
| IGF | insulin-like growth factor |
| IgG | immunoglobulin G |
| IM | intramuscular |
| INSTI | integrase strand transfer inhibitor |
| IPV | intimate partner violence |
| IQR | interquartile range |
| IUD | intrauterine device |
| IUPC | intrauterine pressure catheter |
| IV | intravenous/intravenously |
| LA | long-acting |
| LARC | long-acting reversible contraceptive |
| LAZ | length-for-age z-score |
| LBW | low birth weight |
| MACDP | Metropolitan Atlanta Congenital Defects Program |
| mtDNA | mitochondrial DNA |
| NAT | nucleic acid test |
| NE | norethindrone |
| NHSS | National HIV Surveillance System |
| NICHD | Eunice Kennedy Shriver National Institute of Child Health and Human Development |
| NIH | National Institutes of Health |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NPHIV | non–perinatally acquired HIV |
| NRTI | nucleoside reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OI | opportunistic infection |
| OLE | open-label extension |
| OR | odds ratio |
| The Panel | The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission |
| PBMC | peripheral blood mononuclear cell |
| PBPK | physiologically based pharmacokinetic |
| PCR | polymerase chain reaction |
| PHIV | perinatally acquired HIV |
| PI | protease inhibitor |
| PI/r | ritonavir-boosted protease inhibitor |
| PJP | Pneumocystis jirovecii pneumonia |
| PK | pharmacokinetic |
| POC | point of care |
| POP | progesterone-only oral contraceptive pill |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| PSED | Profile of Social Emotional Development |
| PTB | preterm birth |
| RAM | resistance-associated mutation |
| RCT | randomized controlled trial |
| RDS | respiratory distress syndrome |
| ROM | rupture of membranes |
| SGA | small for gestational age |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| SVR12 | sustained virologic response 12 weeks after completion of treatment |
| TB | tuberculosis |
| TBDR | Texas Birth Defects Registry |
| Tdap | tetanus, diphtheria, and pertussis |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| v/v | volume/volume |
| WAZ | weight-for-age z-score |
| WHO | World Health Organization |
| w/v | weight/volume |
| XR | extended release |
Download Guidelines
- Section Only PDF (74.72 KB)
- Full Guidelines PDF (5.56 MB)
- Recommendations Only PDF (410.31 KB)
- Tables Only PDF (967.23 KB)